Literature DB >> 11095246

Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways.

Z Kadri1, E Petitfrère, C Boudot, J M Freyssinier, S Fichelson, P Mayeux, H Emonard, W Hornebeck, B Haye, C Billat.   

Abstract

In the present study, we demonstrate that erythropoietin (Epo) induces the expression and the release of tissue inhibitors of metalloproteinase-1 (TIMP-1) in a time- and dose-dependent manner in Epo-dependent cell line UT-7 cells and in normal human erythroid progenitor cells from cord blood (CD36+) and required de novo protein synthesis. TIMP-1 was not expressed in the absence of Epo. Inhibition of the mitogen-activated protein kinase pathway by the specific inhibitors PD98059 and U0126 and of phosphatidylinositol 3-kinase by LY294002, strongly inhibited Epo-induced TIMP-1 expression and secretion. In the absence of Epo, both latent and active forms of matrix metalloproteinase-9 (MMP-9) were secreted into media. Upon Epo stimulation, MMP-9 and pro-MMP-9 secretion was inhibited in a dose-dependent manner parallel to TIMP-1 induction. The addition of PD98059, U0126, and LY294002 in the presence of Epo restored MMP-9 production in UT-7 and CD36+ cells. Our findings strongly suggest an inversely coordinated regulation of the TIMP-1 gene and MMP-9 production by Epo via mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095246

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  9 in total

1.  Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia.

Authors:  Rhonda Souvenir; Nancy Fathali; Robert P Ostrowski; Tim Lekic; John H Zhang; Jiping Tang
Journal:  Neurobiol Dis       Date:  2011-06-06       Impact factor: 5.996

Review 2.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

3.  Expression of genes for gelatinases and tissue inhibitors of metalloproteinases in periodontal tissues during orthodontic tooth movement.

Authors:  Ichiro Takahashi; Kazuyuki Onodera; Makoto Nishimura; Hidetoshi Mitnai; Yasuyuki Sasano; Hideo Mitani
Journal:  J Mol Histol       Date:  2006-10-17       Impact factor: 2.611

Review 4.  Erythropoietin in stroke therapy: friend or foe.

Authors:  Rhonda Souvenir; Desislava Doycheva; John H Zhang; Jiping Tang
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

5.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.

Authors:  Amer K Karam; Chintda Santiskulvong; Mirela Fekete; Sara Zabih; Carol Eng; Oliver Dorigo
Journal:  Cytoskeleton (Hoboken)       Date:  2010-08

6.  Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation.

Authors:  Zahra Kadri; Leila Maouche-Chretien; Heather M Rooke; Stuart H Orkin; Paul-Henri Romeo; Patrick Mayeux; Philippe Leboulch; Stany Chretien
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 7.  Erythropoietin: powerful protection of ischemic and post-ischemic brain.

Authors:  Anh Q Nguyen; Brandon H Cherry; Gary F Scott; Myoung-Gwi Ryou; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-04

8.  Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival.

Authors:  Elise Lambert; Cédric Boudot; Zahra Kadri; Mahdhia Soula-Rothhut; Marie-Line Sowa; Patrick Mayeux; William Hornebeck; Bernard Haye; Emmanuelle Petitfrere
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

9.  Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.

Authors:  Andreas N Kapsoritakis; Anastasia I Kapsoritaki; Ioanna P Davidi; Vasilios D Lotis; Anastasios C Manolakis; Petros I Mylonis; Aikaterini T Theodoridou; Anastasios E Germenis; Spyros P Potamianos
Journal:  BMC Gastroenterol       Date:  2008-11-26       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.